Exchange: NASDAQ·Updated 07:59 PM EDT

ACET News

News
all
press releases
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
More News
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
Zacks
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that Chen Schor, President and Chief Executive...
Business Wire
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced completion of the last patient visit for the planned...
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026. One...
Business Wire
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has...
Business Wire
Here's Why You Should Add ACET Stock to Your Portfolio Now
Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.
Zacks
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.
Zacks
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet
The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks

Advertisement|Remove ads.